{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CAMPATH+%28alemtuzumab%29&page=5", "query": { "intervention": "CAMPATH (alemtuzumab)", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 279, "total_pages": 28, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CAMPATH+%28alemtuzumab%29&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CAMPATH+%28alemtuzumab%29&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T02:20:04.596Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00365846", "title": "\"A Pilot Study to Determine the Safety of Campath-1H (Anti-CD52) Therapy in Primary Renal Allograft Transplantation\"", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Renal Transplant" ], "interventions": [ { "name": "Campath-1H", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Wisconsin, Madison", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 29, "start_date": "2000-08", "completion_date": "2006-07", "has_results": true, "last_update_posted_date": "2012-10-03", "last_synced_at": "2026-10-15T02:20:04.596Z", "location_count": 1, "location_summary": "Madison, Wisconsin", "locations": [ { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT00365846" }, { "nct_id": "NCT00566696", "title": "Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia, Acute Lymphocytic (ALL)", "Leukemia, Myeloid, Acute(AML)", "Leukemia, Myeloid, Chronic(CML)", "Juvenile Myelomonocytic Leukemia (JMML)", "Hemoglobinuria, Paroxysmal Nocturnal (PNH)", "Hodgkin Lymphoma", "Lymphoma, Non-Hodgkin (NHL)", "Myelodysplastic Syndrome (MDS)" ], "interventions": [ { "name": "CliniMACS", "type": "DEVICE" }, { "name": "Stem cell transplantation", "type": "PROCEDURE" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Thioplex®", "type": "DRUG" }, { "name": "L-phenylalanine mustard", "type": "DRUG" }, { "name": "Mycophenolate mofetil", "type": "DRUG" }, { "name": "Rituxan™", "type": "DRUG" }, { "name": "Alemtuzumab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Anti-thymocyte globulin (Rabbit)", "type": "DRUG" }, { "name": "G-CSF", "type": "DRUG" }, { "name": "Muromonab", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "PROCEDURE", "DRUG" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 73, "start_date": "2007-12-14", "completion_date": "2020-02-06", "has_results": true, "last_update_posted_date": "2020-04-14", "last_synced_at": "2026-10-15T02:20:04.596Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00566696" }, { "nct_id": "NCT00914758", "title": "Comparison of Campath and Rebif Treatment on Cognition in Multiple Sclerosis (MS)", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Relapsing Remitting Multiple Sclerosis" ], "interventions": [], "intervention_types": [], "sponsor": "Washington Neuropsychology Research Group", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "25 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "25 Years to 50 Years" }, "enrollment_count": 1, "start_date": "2009-03", "completion_date": "2011-12", "has_results": false, "last_update_posted_date": "2009-06-05", "last_synced_at": "2026-10-15T02:20:04.596Z", "location_count": 7, "location_summary": "Berkely, California • Lexington, Kentucky • Springfield, Massachusetts + 4 more", "locations": [ { "city": "Berkely", "state": "California" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Springfield", "state": "Massachusetts" }, { "city": "Lebanon", "state": "New Hampshire" }, { "city": "Latham", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00914758" }, { "nct_id": "NCT01013961", "title": "Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "alemtuzumab", "type": "BIOLOGICAL" }, { "name": "rituximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "ECOG-ACRIN Cancer Research Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "65 Years", "maximum_age": null, "sex": "ALL", "summary": "65 Years and older" }, "enrollment_count": 31, "start_date": "2011-04-27", "completion_date": "2015-04-14", "has_results": true, "last_update_posted_date": "2023-06-28", "last_synced_at": "2026-10-15T02:20:04.596Z", "location_count": 102, "location_summary": "Scottsdale, Arizona • Fort Lauderdale, Florida • Jupiter, Florida + 69 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Jupiter", "state": "Florida" }, { "city": "Miami Beach", "state": "Florida" }, { "city": "Savannah", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01013961" }, { "nct_id": "NCT04018937", "title": "Early Human Leukocyte Antigen (HLA) Matched Sibling Hematopoietic Stem Cell Transplantation", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Sickle Cell Disease" ], "interventions": [ { "name": "Alemtuzumab", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "13 Years", "sex": "ALL", "summary": "2 Years to 13 Years" }, "enrollment_count": 43, "start_date": "2019-03-22", "completion_date": "2026-11", "has_results": false, "last_update_posted_date": "2026-09-24", "last_synced_at": "2026-10-15T02:20:04.596Z", "location_count": 13, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • New Haven, Connecticut + 10 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04018937" }, { "nct_id": "NCT02678143", "title": "Nonmyeloablative Conditioning for Mismatched Hematopoietic Stem Cell Transplantation for Severe Sickle Cell Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Sickle Cell Disease" ], "interventions": [ { "name": "Alemtuzumab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Mycophenolate mofetil", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Total body irradiation", "type": "RADIATION" }, { "name": "Hematopoietic stem cell transplant", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 1, "start_date": "2016-04-26", "completion_date": "2021-11-16", "has_results": false, "last_update_posted_date": "2022-02-14", "last_synced_at": "2026-10-15T02:20:04.596Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT02678143" }, { "nct_id": "NCT00619528", "title": "HLA-Identical Sibling Renal Transplant Tolerance", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Immunosuppression", "Kidney Transplantation", "Graft Rejection" ], "interventions": [ { "name": "Infusion of Donor Hematopoietic Stem Cells and Campath-1H", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 88, "start_date": "2008-01", "completion_date": "2023-09", "has_results": true, "last_update_posted_date": "2026-02-27", "last_synced_at": "2026-10-15T02:20:04.596Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00619528" }, { "nct_id": "NCT00935792", "title": "Everolimus and Alemtuzumab in Treating Patients With Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lymphocytic Leukemia" ], "interventions": [ { "name": "alemtuzumab", "type": "DRUG" }, { "name": "everolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 28, "start_date": "2009-07", "completion_date": "2015-12", "has_results": true, "last_update_posted_date": "2017-09-26", "last_synced_at": "2026-10-15T02:20:04.596Z", "location_count": 2, "location_summary": "Scottsdale, Arizona • Rochester, Minnesota", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00935792" }, { "nct_id": "NCT00548405", "title": "Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Sclerosis, Relapsing-Remitting" ], "interventions": [ { "name": "Alemtuzumab 12 mg", "type": "BIOLOGICAL" }, { "name": "Alemtuzumab 24 mg", "type": "BIOLOGICAL" }, { "name": "Interferon beta-1a", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Genzyme, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 840, "start_date": "2007-10", "completion_date": "2011-09", "has_results": true, "last_update_posted_date": "2017-04-17", "last_synced_at": "2026-10-15T02:20:04.596Z", "location_count": 85, "location_summary": "Cullman, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 71 more", "locations": [ { "city": "Cullman", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00548405" }, { "nct_id": "NCT00771602", "title": "Alemtuzumab + Rituximab Consolidation in CLL", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Lymphocytic Leukemia", "Leukemia" ], "interventions": [ { "name": "Rituximab", "type": "DRUG" }, { "name": "Alemtuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2008-08", "completion_date": "2010-12", "has_results": true, "last_update_posted_date": "2015-06-23", "last_synced_at": "2026-10-15T02:20:04.596Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00771602" } ] }